摘要
β淀粉样蛋白(Aβ)在阿尔茨海默病(AD)发病中起着举足轻重的作用,是一种最有前途的疾病修饰靶点,但在Aβ靶向临床试验中却存在着一系列的失败,提示β是否是真正的病因及有效的治疗靶点。因此,目前的治疗目标和干预策略必须重新考虑。另外Aβ,多种病理事件如tau蛋白过度磷酸化,氧化应激和炎症反应参与了这些疾病的发病机制和病理通路之间产生串扰,协同推动疾病的进展。越来越多的证据也表明,在不同阶段的疾病的发病机制各不相同。因此,针对一个单独的在所有阶段的疾病将不足以阻止或逆转疾病进展。在缺血性发作和AD发展的病理生理之间的相似性,我们可以制定AD从缺血性发作管理的成功实践的管理策略,即三级预防策略。这些新的观点,三级预防的目标是AD病机的不同病理途径和Aβ ,并可能代表一个有前景的方法,有效的预防和治疗措施。
关键词: 阿尔茨海默病,β-淀粉样蛋白,tau蛋白过度磷酸化,中风的治疗策略
Current Alzheimer Research
Title:Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Volume: 13 Issue: 3
Author(s): Xian-Le Bu, Shu-Sheng Jiao, Yan Lian, Yan-Jiang Wang
Affiliation:
关键词: 阿尔茨海默病,β-淀粉样蛋白,tau蛋白过度磷酸化,中风的治疗策略
摘要: Amyloid-beta (Aβ) plays a pivotal role in Alzheimer’s disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials, however, has prompted questions on whether Aβ is the true cause of AD and a valid therapeutic target. Therefore, current therapeutic targets and intervention strategies must be reconsidered. In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress and neuroinflammation are involved in the disease pathogenesis and cause cross-talk between these pathological pathways, which synergistically drive disease progression. Increasing evidence also reveals that the pathogenesis varies at different stages of the disease. Therefore, targeting Aβ alone at all stages of the disease would not be sufficient to halt or reverse disease progression. In the light of the pathophysiologic similarities between the development of ischemic stroke and AD, we can formulate management strategies for AD from the successful practice of ischemic stroke management, namely the tertiary prevention strategy. These new perspectives of tertiary prevention target both Aβ and different pathological pathways of AD pathogenesis at different stages of the disease, and may represent a promising avenue for the effective prevention and treatment of AD.
Export Options
About this article
Cite this article as:
Xian-Le Bu, Shu-Sheng Jiao, Yan Lian, Yan-Jiang Wang , Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151215110114
DOI https://dx.doi.org/10.2174/1567205013666151215110114 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology Based Delivery Systems of Drugs Currently Used to Treat Alzheimer’s Disease
Nanoscience & Nanotechnology-Asia Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Molecular Basis of Familial and Sporadic Alzheimer's Disease
Current Alzheimer Research Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
Current Pharmaceutical Design Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials
Current Pharmaceutical Design Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Therapy in Prion Diseases
Current Topics in Medicinal Chemistry The Premature Lottery in the Canadian Grey Zones
Current Pediatric Reviews Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry The Alzheimer's Disease-Related Glucose Metabolic Brain Pattern
Current Alzheimer Research Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
Current Alzheimer Research Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism